Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.
暂无分享,去创建一个
R C Roovers | R. Schiffelers | G. Storm | R. Roovers | S. Oliveira | P. M. P. van Bergen en Henegouwen | J. van der Veeken | P. V. B. Henegouwen | P M P van Bergen En Henegouwen | R M Schiffelers | G Storm | J van der Veeken | S Oliveira | J. V. D. Veeken
[1] David R Davies,et al. The type 1 insulin‐like growth factor receptor is over‐expressed in bladder cancer , 2007, BJU international.
[2] Joseph Schlessinger,et al. A Novel Positive Feedback Loop Mediated by the Docking Protein Gab1 and Phosphatidylinositol 3-Kinase in Epidermal Growth Factor Receptor Signaling , 2000, Molecular and Cellular Biology.
[3] E. Bruyneel,et al. Insulin‐like growth factor‐I receptor, E‐cadherin and αv integrin form a dynamic complex under the control of α‐catenin , 2008 .
[4] Y. Yarden,et al. A mutant EGF‐receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling , 2002, The EMBO journal.
[5] M. Pollak. Targeting insulin and insulin-like growth factor signalling in oncology. , 2008, Current opinion in pharmacology.
[6] D. Sabatini,et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.
[7] J. Downward,et al. Autophosphorylation sites on the epidermal growth factor receptor , 1984, Nature.
[8] C. Kahn,et al. A cascade of tyrosine autophosphorylation in the beta-subunit activates the phosphotransferase of the insulin receptor. , 1988, The Journal of biological chemistry.
[9] H Steven Wiley,et al. Trafficking of the ErbB receptors and its influence on signaling. , 2003, Experimental cell research.
[10] R. Davis,et al. Protein tyrosine kinase activities of the epidermal growth factor receptor and ErbB proteins: correlation of oncogenic activation with altered kinetics , 1992, Molecular and cellular biology.
[11] J. Grandis,et al. STAT‐mediated EGFR signaling in cancer , 2007, Journal of cellular biochemistry.
[12] Yuji Saito,et al. Receptor Heterodimerization: Essential Mechanism for Platelet-Derived Growth Factor-Induced Epidermal Growth Factor Receptor Transactivation , 2001, Molecular and Cellular Biology.
[13] S. Sugano,et al. Large-scale identification and characterization of human genes that activate NF-κB and MAPK signaling pathways , 2003, Oncogene.
[14] Arnab Chakravarti,et al. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. , 2002, Cancer research.
[15] Z. Werb,et al. G protein–coupled receptors , 2002 .
[16] M. Kanzaki,et al. CAP defines a second signalling pathway required for insulin-stimulated glucose transport , 2000, Nature.
[17] S. J. Taylor,et al. Insulin-like growth factor I receptor signaling in transformation by src oncogenes , 1997, Molecular and cellular biology.
[18] M. Rubini,et al. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[19] Julian Downward,et al. EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2 , 1997, Oncogene.
[20] J. Massagué,et al. Membrane-anchored growth factors. , 1993, Annual review of biochemistry.
[21] Analysis of the transcriptional program induced by Raf in epithelial cells , 2001 .
[22] N. Lydon,et al. Src Phosphorylation of the Epidermal Growth Factor Receptor at Novel Sites Mediates Receptor Interaction with Src and P85α (*) , 1995, The Journal of Biological Chemistry.
[23] J. Carethers,et al. RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells. , 2007, Carcinogenesis.
[24] R. Kurzrock,et al. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials , 2008, Molecular Cancer Therapeutics.
[25] G. Cooper,et al. Role of Glycogen Synthase Kinase-3 in the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway* , 1998, The Journal of Biological Chemistry.
[26] E. Petricoin,et al. Dynamic Profiling of the Post-translational Modifications and Interaction Partners of Epidermal Growth Factor Receptor Signaling after Stimulation by Epidermal Growth Factor Using Extended Range Proteomic Analysis (ERPA)*S , 2006, Molecular & Cellular Proteomics.
[27] R. Lefkowitz,et al. β-Arrestins Regulate Mitogenic Signaling and Clathrin-mediated Endocytosis of the Insulin-like Growth Factor I Receptor* , 1998, The Journal of Biological Chemistry.
[28] T. Jensen,et al. PLD2 Complexes with the EGF Receptor and Undergoes Tyrosine Phosphorylation at a Single Site upon Agonist Stimulation* , 1998, The Journal of Biological Chemistry.
[29] S. Hankinson,et al. Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.
[30] C. Ward,et al. Systematic Mapping of Potential Binding Sites for Shc and Grb2 SH2 Domains on Insulin Receptor Substrate-1 and the Receptors for Insulin, Epidermal Growth Factor, Platelet-derived Growth Factor, and Fibroblast Growth Factor (*) , 1996, The Journal of Biological Chemistry.
[31] Nathan E Hall,et al. CR1/CR2 Interactions Modulate the Functions of the Cell Surface Epidermal Growth Factor Receptor* , 2004, Journal of Biological Chemistry.
[32] Y. Yarden,et al. ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.
[33] Véronique Delmas,et al. IGF-II induces rapid β-catenin relocation to the nucleus during epithelium to mesenchyme transition , 2001, Oncogene.
[34] W. Miller,et al. Role of the Activation Loop Tyrosines in Regulation of the Insulin-like Growth Factor I Receptor-tyrosine Kinase* , 2006, Journal of Biological Chemistry.
[35] John Kuriyan,et al. An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.
[36] Ji-ping Wang,et al. Long-term Treatment with Tamoxifen Facilitates Translocation of Estrogen Receptor α out of the Nucleus and Enhances its Interaction with EGFR in MCF-7 Breast Cancer Cells , 2007 .
[37] C. Blobel,et al. Ectodomain shedding of the EGF‐receptor ligand epigen is mediated by ADAM17 , 2007, FEBS letters.
[38] Zeguang Han,et al. siRNA mediated the type 1 insulin-like growth factor receptor and epidermal growth factor receptor silencing induces chemosensitization of liver cancer cells , 2008, Journal of Cancer Research and Clinical Oncology.
[39] B. Leyland-Jones,et al. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. , 2006, Cancer research.
[40] Takao Shimizu,et al. Regulatory mechanism and physiological role of cytosolic phospholipase A2. , 2004, Biological & pharmaceutical bulletin.
[41] T. Roberts,et al. Tangled Webs: Evidence of Cross-Talk Between c-Raf-1 and Akt , 1999, Science's STKE.
[42] S. Muyldermans,et al. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. , 1994, Protein engineering.
[43] R. Nicholson,et al. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (‘Iressa’) response and resistance , 2008, Breast Cancer Research and Treatment.
[44] S. McColl,et al. Transactivation of CXCR4 by the Insulin-like Growth Factor-1 Receptor (IGF-1R) in Human MDA-MB-231 Breast Cancer Epithelial Cells* , 2005, Journal of Biological Chemistry.
[45] A. Rishi,et al. Curcumin enhances the effects of 5‐fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF‐1R , 2008, International journal of cancer.
[46] R. Baxter,et al. Cellular actions of the insulin-like growth factor binding proteins. , 2002, Endocrine reviews.
[47] R. Kobayashi,et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells (Cancer Research (2005) 65, (11118-11128)) , 2008 .
[48] Adrian V. Lee,et al. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. , 2006, Cancer research.
[49] M. Mann,et al. Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.
[50] Dennis C. Sgroi,et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis , 2003, Nature Cell Biology.
[51] Hyun-soo Cho,et al. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. , 2003, Molecular cell.
[52] A. Mauviel,et al. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-β: implications for carcinogenesis , 2005, Oncogene.
[53] Roger J. Davis,et al. cPLA2 is phosphorylated and activated by MAP kinase , 1993, Cell.
[54] D. Bar-Sagi,et al. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. , 2004, Cancer cell.
[55] Monilola A. Olayioye,et al. The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.
[56] G. Carpenter,et al. Phospholipase C-gamma1: regulation of enzyme function and role in growth factor-dependent signal transduction. , 1997, Cytokine & growth factor reviews.
[57] N. Hynes,et al. ErbB receptors: directing key signaling networks throughout life. , 2004, Annual review of pharmacology and toxicology.
[58] J. Bos,et al. cAMP antagonizes p21ras‐directed activation of extracellular signal‐regulated kinase 2 and phosphorylation of mSos nucleotide exchange factor. , 1993, The EMBO journal.
[59] D. Hanahan,et al. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. , 2002, Cancer cell.
[60] D. A. Foster,et al. Phospholipase D in cell proliferation and cancer. , 2003, Molecular cancer research : MCR.
[61] T. Giordano,et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. , 2005, Cancer cell.
[62] T M Jovin,et al. Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation , 1995, The Journal of cell biology.
[63] Stevan R. Hubbard,et al. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase , 2001, Nature Structural Biology.
[64] P. Goss,et al. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. , 2008, The oncologist.
[65] S. Parsons,et al. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[66] Matthias Egger,et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.
[67] Kohjiro Ueki,et al. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone , 1997, Nature.
[68] K. Rabe,et al. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. , 2007, Lung cancer.
[69] Antony W Burgess,et al. Epidermal growth factor receptor: mechanisms of activation and signalling. , 2003, Experimental cell research.
[70] A Ciechanover,et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. , 1999, Molecular cell.
[71] A. Ullrich,et al. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells , 1987, Cell.
[72] Jae-Hoon Kim,et al. Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.
[73] O. Larsson,et al. β-Arrestin Is Crucial for Ubiquitination and Down-regulation of the Insulin-like Growth Factor-1 Receptor by Acting as Adaptor for the MDM2 E3 Ligase* , 2005, Journal of Biological Chemistry.
[74] C. R. Leemans,et al. Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology , 2008, Molecular Cancer Therapeutics.
[75] M. Maa,et al. c-Src-mediated Phosphorylation of the Epidermal Growth Factor Receptor on Tyr845 and Tyr1101 Is Associated with Modulation of Receptor Function* , 1999, The Journal of Biological Chemistry.
[76] S. Jenna,et al. Extracellular Signal-Regulated Kinase 1 Interacts with and Phosphorylates CdGAP at an Important Regulatory Site , 2005, Molecular and Cellular Biology.
[77] Hai-Tao He,et al. Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. , 2008, Nature chemical biology.
[78] R. Bonavia,et al. Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. , 2005, Experimental cell research.
[79] Edouard C. Nice,et al. Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.
[80] Stefan Hart,et al. TACE cleavage of proamphiregulin regulates GPCR‐induced proliferation and motility of cancer cells , 2003, The EMBO journal.
[81] G. Weskamp,et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands , 2004, The Journal of cell biology.
[82] P. Sorensen,et al. The Insulin-Like Growth Factor I Receptor Is Required for Akt Activation and Suppression of Anoikis in Cells Transformed by the ETV6-NTRK3 Chimeric Tyrosine Kinase , 2006, Molecular and Cellular Biology.
[83] A. Chakraborty,et al. Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. , 2008, Cancer research.
[84] R. Poulsom,et al. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. , 2002, Cancer research.
[85] D. Bar-Sagi,et al. Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos , 2007, Nature Cell Biology.
[86] J. Olefsky,et al. The signaling pathway coupling epidermal growth factor receptors to activation of p21ras. , 1994, The Journal of biological chemistry.
[87] E. Henson,et al. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. , 2006, Cellular signalling.
[88] S. R. Datta,et al. Transcription-dependent and -independent control of neuronal survival by the PI3K–Akt signaling pathway , 2001, Current Opinion in Neurobiology.
[89] D. Coppola,et al. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor , 1994, Molecular and cellular biology.
[90] Domenico Coppola,et al. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. , 2003, Human pathology.
[91] H. Werner,et al. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[92] Phillip T. Hawkins,et al. Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ , 2000, Cell.
[93] Y. Yarden. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.
[94] M. Zvelebil,et al. Class II Phosphoinositide 3-Kinases Are Downstream Targets of Activated Polypeptide Growth Factor Receptors , 2000, Molecular and Cellular Biology.
[95] K. L. Pierce,et al. Transactivation of the EGF Receptor Mediates IGF-1-stimulated Shc Phosphorylation and ERK1/2 Activation in COS-7 Cells* , 2000, The Journal of Biological Chemistry.
[96] P. Marin,et al. GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation. , 2007, Trends in pharmacological sciences.
[97] W. Jiang,et al. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue , 2006, Breast Cancer Research and Treatment.
[98] S. Muyldermans,et al. Naturally occurring antibodies devoid of light chains , 1993, Nature.
[99] W. Gullick,et al. Identification of c‐erbB‐3 binding sites for phosphatidylinositol 3′‐kinase and SHC using an EGF receptor/c‐erbB‐3 chimera. , 1994, The EMBO journal.
[100] D. Yee,et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. , 2008, The Journal of clinical investigation.
[101] R. O'Connor,et al. Regulation of IGF-I Receptor Signaling in Tumor Cells , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[102] D. Proud,et al. Effects of tumor necrosis factor-α, epidermal growth factor and transforming growth factor-α on interleukin-8 production by, and human rhinovirus replication in, bronchial epithelial cells , 2001 .
[103] R. Santen,et al. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. , 2007, Endocrinology.
[104] I. Maruyama,et al. Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. , 2001, Journal of molecular biology.
[105] Yi Wang,et al. Akt binds to and phosphorylates phospholipase C-gamma1 in response to epidermal growth factor. , 2006, Molecular biology of the cell.
[106] R. Nicholson,et al. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. , 2005, Endocrinology.
[107] A. Lenferink,et al. Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers , 1998, The EMBO journal.
[108] J. Gutkind,et al. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. , 2001, Biochemical and biophysical research communications.
[109] Edward S. Kim,et al. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. , 2006, Cancer research.
[110] A. Ullrich,et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences , 1984, Nature.
[111] N. Hynes,et al. Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells , 2003 .
[112] A. Ullrich,et al. Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion , 2004, Oncogene.
[113] J. Watson,et al. Cloning and Biological Activity of Epigen, a Novel Member of the Epidermal Growth Factor Superfamily* , 2001, The Journal of Biological Chemistry.
[114] S. Keyse,et al. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases , 2007, Oncogene.
[115] Michael Kofler,et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. , 2003, Molecular cell.
[116] D. O'Gorman,et al. Insulin-like growth factor-II/mannose 6-phosphate receptor overexpression reduces growth of choriocarcinoma cells in vitro and in vivo. , 2002, Endocrinology.
[117] J. Schlessinger,et al. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor , 1994, Molecular and cellular biology.
[118] D. Seals,et al. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. , 2003, Genes & development.
[119] T. Fujii,et al. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. , 2008, Cancer research.
[120] D A Lauffenburger,et al. The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. , 1991, The Journal of biological chemistry.
[121] O. Larsson,et al. Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis. , 2008, Cancer research.
[122] A. Verkleij,et al. Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies , 2007, Cancer Immunology, Immunotherapy.
[123] Lewis C Cantley,et al. The phosphoinositide 3-kinase pathway. , 2002, Science.
[124] C. Ward,et al. Structure and function of the type 1 insulin-like growth factor receptor , 2000, Cellular and Molecular Life Sciences CMLS.
[125] S. Gammeltoft,et al. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction , 1999, Molecular and Cellular Endocrinology.
[126] D. Hicklin,et al. A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity* , 2005, Journal of Biological Chemistry.
[127] A. Ullrich,et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling , 1992, Cell.
[128] G. V. van Dongen,et al. Nanobodies in therapeutic applications. , 2007, Current opinion in molecular therapeutics.
[129] W. V. van Blitterswijk,et al. Protein Kinase Cζ Is a Negative Regulator of Protein Kinase B Activity* , 1999, The Journal of Biological Chemistry.
[130] Ryuji Kobayashi,et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.
[131] P. Transidico,et al. Clathrin-independent endocytosis of ubiquitinated cargos. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[132] F. Khuri,et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. , 2005, Cancer research.
[133] F. Schliess,et al. Hyperosmolarity and CD95L trigger CD95/EGFR association and tyrosine phosphorylation of CD95 as prerequisites for CD95 membrane trafficking and DISC formation , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[134] A. Pendergast,et al. Abl Tyrosine Kinase Regulates Endocytosis of the Epidermal Growth Factor Receptor* , 2006, Journal of Biological Chemistry.
[135] Angelo Paradiso,et al. The complexity of targeting EGFR signalling in cancer: from expression to turnover. , 2006, Biochimica et biophysica acta.
[136] S. Bao,et al. The activation of Akt/PKB signaling pathway and cell survival , 2005, Journal of cellular and molecular medicine.